Skip to main
BEAT

HeartBeam (BEAT) Stock Forecast & Price Target

HeartBeam (BEAT) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

HeartBeam is well positioned in the growing market of remote patient monitoring and is already seeing traction with the initial commercial launch of its hand-held 12-lead ECG and the initiation of a pilot study for its extended-wear ECG patch. The recent $11.5M equity offering strengthens the company's cash position and will help support its operations. HeartBeam's technology platform has the potential to significantly improve physicians' ability to diagnose conditions such as arrhythmias and ischemia in a more efficient and accurate manner, making it a promising investment opportunity for those with a positive long-term outlook.

Bears say

HeartBeam is a small company and faces several significant risks that could impact its commercial success, including potential failures in clinical trials for expanded indications and challenges in achieving market success due to competition and size limitations. Additionally, the company's reliance on a patient-pay model and the need for future capital raises could result in dilution for shareholders. Despite the potential for a large market opportunity in the growing remote patient monitoring space, the company may face hurdles in adoption and reimbursement for its technology. Its intellectual property portfolio provides a competitive advantage, but continued innovation and potential enforcement may be necessary to stay ahead of larger competitors.

HeartBeam (BEAT) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of HeartBeam and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About HeartBeam (BEAT) Forecast

Analysts have given HeartBeam (BEAT) a Strong Buy based on their latest research and market trends.

According to 4 analysts, HeartBeam (BEAT) has a Strong Buy consensus rating as of Jun 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

HeartBeam (BEAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.